

# Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

## SK-BR-3

RRID:CVCL\_0033

Type: Cell Line

### Proper Citation

RRID:CVCL\_0033

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0033](https://web.expasy.org/cellosaurus/CVCL_0033)

**Proper Citation:** RRID:CVCL\_0033

**Description:** Cell line SK-BR-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Breast adenocarcinoma

**Defining Citation:** [PMID:327080](#), [PMID:833871](#), [PMID:1013510](#), [PMID:1961733](#), [PMID:3518877](#), [PMID:6401685](#), [PMID:6500159](#), [PMID:6582512](#), [PMID:6935474](#), [PMID:7017212](#), [PMID:9671407](#), [PMID:10862037](#), [PMID:10969801](#), [PMID:11044355](#), [PMID:11343771](#), [PMID:12800145](#), [PMID:15677628](#), [PMID:16397213](#), [PMID:16417655](#), [PMID:16541312](#), [PMID:16957166](#), [PMID:17157791](#), [PMID:17334996](#), [PMID:18516279](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:19727395](#), [PMID:20070913](#), [PMID:20215515](#), [PMID:20407441](#), [PMID:21247443](#), [PMID:21378333](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:23671654](#), [PMID:24009699](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:24389870](#), [PMID:24456987](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25960936](#), [PMID:26055192](#), [PMID:26378940](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:28889351](#), [PMID:29273624](#), [PMID:29954844](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32942617](#)

**Comments:** Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870)., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** SK-BR-3

**Synonyms:** SK-Br-3, Sk-Br-3, SK BR 03, SKBR-3, SKBr-3, SK-BR3, SKBr3, SkBr3, SKBR3

**Cross References:** BTO:BTO\_0002419, CLO:CLO\_0009034, CLO:CLO\_0037295, EFO:EFO\_0001236, MCCL:MCC:0000424, CLDB:cl4310, CLDB:cl7143, AddexBio:C0006007/65, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-30, BCRJ:0226, BioGRID\_ORCS\_Cell\_line:378, BioSample:SAMN01821597, BioSample:SAMN03471462, BioSample:SAMN10987910, cancercellines:CVCL\_0033, CancerTools:161911, CCRID:1101HUM-PUMC000085, CCRID:3101HUMTCHu225, CCRID:4201HUM-CCTCC00286, CCTCC:GDC0286, Cell\_Model\_Passport:SIDM00897, ChEMBL-Cells:ChEMBL3308062, ChEMBL-Targets:ChEMBL613834, CLS:300333, Cosmic:687499, Cosmic:755294, Cosmic:759896, Cosmic:871159, Cosmic:894090, Cosmic:897742, Cosmic:904385, Cosmic:921974, Cosmic:923062, Cosmic:934531, Cosmic:944297, Cosmic:979713, Cosmic:991329, Cosmic:997935, Cosmic:1000127, Cosmic:1010922, Cosmic:1018478, Cosmic:1044209, Cosmic:1046958, Cosmic:1129655, Cosmic:1136357, Cosmic:1176645, Cosmic:1287914, Cosmic:1289405, Cosmic:1308997, Cosmic:1434957, Cosmic:1524342, Cosmic:1571789, Cosmic:1609462, Cosmic:2036669, Cosmic:2165013, Cosmic:2301535, Cosmic:2318379, Cosmic:2361351, DepMap:ACH-000017, DSMZ:ACC-736, DSMZCellDive:ACC-736, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM69195, GEO:GSM73742, GEO:GSM115115, GEO:GSM149978, GEO:GSM149986, GEO:GSM149994, GEO:GSM152556, GEO:GSM152557, GEO:GSM152558, GEO:GSM152559, GEO:GSM154096, GEO:GSM154097, GEO:GSM154098, GEO:GSM154099, GEO:GSM154100, GEO:GSM154101, GEO:GSM154102, GEO:GSM154104, GEO:GSM154107, GEO:GSM155215, GEO:GSM170624, GEO:GSM170625, GEO:GSM170626, GEO:GSM170627, GEO:GSM170630, GEO:GSM170631, GEO:GSM170633, GEO:GSM170634, GEO:GSM183440, GEO:GSM183441, GEO:GSM186457, GEO:GSM186458, GEO:GSM217596, GEO:GSM274644, GEO:GSM274663, GEO:GSM344357, GEO:GSM344407, GEO:GSM350501, GEO:GSM378146, GEO:GSM421883, GEO:GSM481334, GEO:GSM590106, GEO:GSM595617, GEO:GSM783927, GEO:GSM827582, GEO:GSM844686, GEO:GSM844687, GEO:GSM845399, GEO:GSM847432, GEO:GSM847499, GEO:GSM887575, GEO:GSM888658, GEO:GSM1008913, GEO:GSM1038850, GEO:GSM1038851, GEO:GSM1038852, GEO:GSM1038853, GEO:GSM1038854, GEO:GSM1053720, GEO:GSM1172895, GEO:GSM1172989, GEO:GSM1214572, GEO:GSM1238124, GEO:GSM1264069, GEO:GSM1264074, GEO:GSM1264111, GEO:GSM1264116, GEO:GSM1374872, GEO:GSM1374873, GEO:GSM1374874, GEO:GSM1401659, GEO:GSM1661988, GEO:GSM1833627, GEO:GSM2258794, GEO:GSM2258795, GEO:GSM2258796, GEO:GSM2258797, GEO:GSM2258798, GEO:GSM2258799, GEO:GSM2258800, GEO:GSM2258801, GEO:GSM2258802, GEO:GSM2258803, GEO:GSM2258804, GEO:GSM2258805, GEO:GSM2258806, GEO:GSM2258807, GEO:GSM2258808, GEO:GSM2258809, GEO:GSM2258810, GEO:GSM2258811, GEO:GSM2258950, GEO:GSM2258951, GEO:GSM2258952, GEO:GSM7701439, GEO:GSM7701440, Hysigen:TCH-C328, IARC\_TP53:580, IBRC:C10147, ICLC:HTL03005, IPD-IMGT/HLA:12368, IZSLER:BS TCL 156, KCB:KCB 200723YJ,

KCLB:30030, LiGeA:CCLE\_391, LINC\_S\_HMS:50057, LINC\_S\_LDP:LCL-1475, Lonza:70, NCBI\_Iran:C207, PharmacDB:SKBR3\_1383\_2019, PRIDE:PXD000691, PRIDE:PXD002053, PRIDE:PXD002057, PRIDE:PXD002281, PRIDE:PXD002486, PRIDE:PXD005390, PRIDE:PXD008222, Progenetix:CVCL\_0033, PubChem\_Cell\_line:CVCL\_0033, RCB:RCB2132, SLKBase:3618, TKG:TKG 0592, TOKU-E:3129, Ubigen:YC-C048, Wikidata:Q7390592

**ID:** CVCL\_0033

**Record Creation Time:** 20220427T221544+0000

**Record Last Update:** 20260829T235934+0000

---

## Ratings and Alerts

No rating or validation information has been found for SK-BR-3.

**Warning:** Discontinued: TKG; TKG 0592

Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870)., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Warning:** Discontinued: RCB; RCB2132

Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870)., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 3515 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer research, 86(6), 1467.

Ochtrop P, et al. (2026) Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. Nature communications, 17(1), 759.

Demel UM, et al. (2026) Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(17), e11449.

Luque M, et al. (2026) Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer. *Neoplasia* (New York, N.Y.), 78, 101318.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. *Cell reports. Medicine*, 7(7), 102922.

Ranganathan S, et al. (2026) Gasdermin D Cleavage and Cytokine Release, Indicative of Pyroptotic Cell Death, Induced by Ophiobolin A in Breast Cancer Cell Lines. *International journal of molecular sciences*, 27(2).

Burnham CM, et al. (2026) An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates. *The Journal of biological chemistry*, 302(4), 111302.

Sun Y, et al. (2026) CircNSD2 promotes metastasis and immune escape by increasing the USP10/SRSF6-mediated alternative splicing of TPM1 in TNBC. *Molecular cancer*, 25(1).

Wang ZW, et al. (2026) Combinatorial inhibition of IGF2BP3-regulated receptor tyrosine kinases offers a new therapeutic strategy for triple-negative breast cancer. *Journal of experimental & clinical cancer research : CR*, 45(1).

He G, et al. (2026) Vesicle trafficking 1 in breast cancer tissue and serum orchestrates metastatic progression and an immunosuppressive microenvironment. *International immunopharmacology*, 178, 116564.

Yao Y, et al. (2026) Identification and validation of a seven-gene metastasis-associated prognostic model in breast cancer. *Frontiers in genetics*, 17, 1770418.

Dang X, et al. (2026) Modular Assembly of Bioconjugates Enabled by a Pyridine-Based Chemoselective Sequential Conjugation Platform. *Angewandte Chemie (International ed. in English)*, e3286230.

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. *Cell reports*, 45(2), 116882.

Lin X, et al. (2026) 99mTc-HP-Ark2 SPECT/CT imaging reveals dynamic HER2 regulation in trastuzumab resistance and its reversal by PI3K inhibition. *International journal of cancer*, 158(6), 1726.

Samanta A, et al. (2026) Bacteriophage-Mimetic DNA Origami Needle for Targeted Membrane Penetration and Cytosolic Cargo Delivery. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(10), e12844.

Boz AB, et al. (2026) AXL-Driven Stemness and Hedgehog Signaling in HER2-Positive Breast Cancer with Acquired Trastuzumab Resistance: Synergistic Potential of AXL and HER2 Co-Targeting. *Life* (Basel, Switzerland), 16(3).

Venkatesh J, et al. (2026) LINC01929 mediates breast cancer immunosuppression and is an immunotherapy target. *iScience*, 29(4), 115381.

El Sahili A, et al. (2026) Antibody-drug-conjugates prepared with Peptide Asparaginyl Ligases achieve strong in vitro and in vivo anti-tumor activity. *Molecular cancer therapeutics*.

Qiu Z, et al. (2026) NUP62 promotes breast cancer progression and inhibits ferroptosis by stabilizing NRF2 in a KEAP1-dependent way. *iScience*, 29(5), 115484.

Liu J, et al. (2026) Targeting the noncanonical function of metabolic enzyme PHGDH in driving PD-L1 expression and cancer immune evasion. *Cell reports. Medicine*, 7(4), 102704.